Esperion Therapeutics, Inc.: cash and cash equivalents
Cash and cash equivalents for Esperion Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Esperion Therapeutics, Inc. financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 167,852,000 | USD | 2026-03-10 | 10-K · 0001628280-26-016522 |
| At date | 2024-12-31 | 144,761,000 | USD | 2026-03-10 | 10-K · 0001628280-26-016522 |
| At date | 2023-12-31 | 82,248,000 | USD | 2025-03-07 | 10-K · 0001628280-25-011154 |
| At date | 2022-12-31 | 124,775,000 | USD | 2024-02-27 | 10-K · 0001628280-24-007066 |
| At date | 2021-12-31 | 208,892,000 | USD | 2023-02-21 | 10-K · 0001628280-23-004167 |
| At date | 2020-12-31 | 304,962,000 | USD | 2022-02-22 | 10-K · 0001628280-22-003263 |
| At date | 2019-12-31 | 166,130,000 | USD | 2021-02-23 | 10-K · 0001628280-21-002865 |
| At date | 2018-12-31 | 36,973,000 | USD | 2020-02-27 | 10-K · 0001104659-20-026203 |
| At date | 2017-12-31 | 34,468,000 | USD | 2019-02-28 | 10-K · 0001047469-19-000791 |
| At date | 2016-12-31 | 38,165,000 | USD | 2018-02-20 | 10-K · 0001047469-18-000899 |
| At date | 2015-12-31 | 77,336,000 | USD | 2018-02-20 | 10-K · 0001047469-18-000899 |
| At date | 2014-12-31 | 85,038,000 | USD | 2018-02-20 | 10-K · 0001047469-18-000899 |
| At date | 2013-12-31 | 56,537,000 | USD | 2017-02-22 | 10-K · 0001047469-17-000831 |
| At date | 2012-12-31 | 6,512,000 | USD | 2016-02-25 | 10-K · 0001047469-16-010437 |
| At date | 2011-12-31 | 1,571,000 | USD | 2015-03-10 | 10-K · 0001047469-15-001908 |
| At date | 2010-12-31 | 3,414,896 | USD | 2014-03-13 | 10-K · 0001047469-14-002320 |
Related financial histories
- Esperion Therapeutics, Inc.: total assets
- Esperion Therapeutics, Inc.: total liabilities
- Esperion Therapeutics, Inc.: stockholders equity
- Esperion Therapeutics, Inc.: net income or loss
- Esperion Therapeutics, Inc.: operating cash flow
- Esperion Therapeutics, Inc.: capital expenditure payments
- Esperion Therapeutics, Inc.: contract revenue excluding tax
- Esperion Therapeutics, Inc.: financing cash flow
- Esperion Therapeutics, Inc.: investing cash flow
- Esperion Therapeutics, Inc.: retained earnings or deficit
- Esperion Therapeutics, Inc.: basic weighted-average shares
- Esperion Therapeutics, Inc.: diluted weighted-average shares
- Esperion Therapeutics, Inc.: basic earnings per share
- Esperion Therapeutics, Inc.: diluted earnings per share
- Esperion Therapeutics, Inc.: income tax expense or benefit
- Esperion Therapeutics, Inc.: net property, plant and equipment
- Esperion Therapeutics, Inc.: share-based compensation expense
- Esperion Therapeutics, Inc.: operating income or loss
- Esperion Therapeutics, Inc.: current assets
- Esperion Therapeutics, Inc.: interest expense
- Esperion Therapeutics, Inc.: current liabilities
- Esperion Therapeutics, Inc.: current accounts payable
- Esperion Therapeutics, Inc.: net current accounts receivable
- Esperion Therapeutics, Inc.: common-stock repurchase payments
- Esperion Therapeutics, Inc.: operating expenses
- Esperion Therapeutics, Inc.: net inventory
- Esperion Therapeutics, Inc.: selling, general and administrative expense
- Esperion Therapeutics, Inc.: common shares outstanding
- Esperion Therapeutics, Inc.: cash including restricted cash
- Esperion Therapeutics, Inc.: additional paid-in capital
- Esperion Therapeutics, Inc.: accumulated other comprehensive income or loss
- Esperion Therapeutics, Inc.: operating lease right-of-use asset
- Esperion Therapeutics, Inc.: operating lease liability
- Esperion Therapeutics, Inc.: gross property, plant and equipment
- Esperion Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
- Esperion Therapeutics, Inc.: other noncurrent liabilities
- Esperion Therapeutics, Inc.: prepaid expenses and other current assets
- Esperion Therapeutics, Inc.: current contract liabilities
- Esperion Therapeutics, Inc.: pre-tax income or loss from continuing operations
- Esperion Therapeutics, Inc.: profit or loss including noncontrolling interests
- Esperion Therapeutics, Inc.: comprehensive income or loss
- Esperion Therapeutics, Inc.: general and administrative expense
- Esperion Therapeutics, Inc.: depreciation expense
- Esperion Therapeutics, Inc.: nonoperating interest expense
- Esperion Therapeutics, Inc.: other nonoperating income or expense
- Esperion Therapeutics, Inc.: current income tax expense or benefit
- Esperion Therapeutics, Inc.: interest paid, net
- Esperion Therapeutics, Inc.: income taxes paid, net
- Esperion Therapeutics, Inc.: proceeds from issuing common stock
- Esperion Therapeutics, Inc.: operating lease payments
- Esperion Therapeutics, Inc.: change in accounts receivable
- Esperion Therapeutics, Inc.: change in inventories
- Esperion Therapeutics, Inc.: change in accounts payable
Inspect the source
- Entity
- Esperion Therapeutics, Inc. / CIK 0001434868
- Captured
- 2026-09-21T17:19:05.322Z
- SEC response SHA-256
c855d6a6c2d879a88675aebb590fdc9935826605a25a04ffeec1282218bce6bf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001434868.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))